Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage

Nature Protocols

Volumn 6, Issue 3, 2011, Pages 388-404

  Stanton, Heather ^a,b   Golub, Suzanne B ^a,b   Rogerson, Fraser M ^a,b   Last, Karena ^a,b   Little, Christopher B ^a,c,d   Fosang, Amanda J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE;

ACCURACY; ANIMAL TISSUE; ARTICLE; CARTILAGE; CARTILAGE DEGENERATION; COLORIMETRY; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME RELEASE; FEMUR HEAD; GENE MUTATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ADAM PROTEINS; AGGRECANS; ANIMALS; ARTHRITIS; BLOTTING, WESTERN; CARTILAGE; METHYLENE BLUE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 79952405776     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2010.179     Document Type: Article

References (76)

1. Hascall, V.C., Sandy, J.D. & Handley, C.J. In Biology of the Synovial Joint (eds. Caterson, B., Archer, C., Benjamin, M. & Ralph, J.) (Harwood Academic Publishers, 1999).
2. Caterson, B., Flannery, C.R., Hughes, C.E. & Little, C.B. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 19, 333-344 (2000). (Pubitemid 30665657)
3. Fosang, AJ., Tyler, J.A. & Hardingham, T.E. Effect of interleukin-1 and insulin-like growth factor-1 on the degradation and turnover of proteoglycan and hyaluronate in pig articular cartilage in explant culture. Matrix 11, 17-24 (1991).
4. Fosang, AJ. et al. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J. Biol. Chem. 275, 33027-33037 (2000).
5. Tortorella, M.D., Malfait, A., Deccico, C & Arner, E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthr. Cartil. 9, 539-552 (2001). (Pubitemid 32842633)
6. Durigova, M. et al. Characterization of an ADAMTS-5-mediated cleavage site in aggrecan in OSM-stimulated bovine cartilage. Osteoarthr. Cartil. 16, 1245-1252 (2008).
7. Sztrolovics, R., White, RJ., Roughley, PJ. & Mort, J.S. The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism. Biochem. J. 362, 465-472 (2002). (Pubitemid 34214490)
8. Sandy, J.D. & Verscharen, C Analysis of aggrecan in human knee cartilage and synovial fuid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem. J. 358, 615-626 (2001). (Pubitemid 32896949)
9. Ilic, M.Z., Handley, CJ., Robinson, H.C. & Mok, M.T. Mechanism of catabolism of aggrecan by articular cartilage. Archiv. Biochem. Biophys. 294, 115-122 (1992).
10. Sandy, J.D., Neame, P.J., Boynton, R.E. & Flannery, C.R. Catabolism of aggrecan in cartilage explants. Identifcation of a major cleavage site within the interglobular domain. J. Biol. Chem. 266, 8683-8685 (1991). (Pubitemid 21906567)
11. Loulakis, P., Shrikhande, A., Davis, G. & Maniglia, C.A. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem. J. 284 (Part 2): 589-593 (1992).
12. Rogerson, F.M. et al. Evidence of a novel aggrecan-degrading activity in cartilage: studies of mice defcient in both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 58, 1664-1673 (2008). (Pubitemid 351847519)
13. Stanton, H. et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434, 648-652 (2005). (Pubitemid 40488557)
14. East, CJ., Stanton, H., Golub, S.B., Rogerson, F.M. & Fosang, AJ. ADAMTS-5 defciency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulphate-rich region of aggrecan. J. Biol. Chem. 282, 8632-8640 (2007). (Pubitemid 47093500)
15. Ilic, M.Z., East, C.J., Rogerson, F.M., Fosang, AJ. & Handley, C.J. Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double defcient mice. J. Biol. Chem. 282, 37420-37428 (2007).
16. Little, C.B. et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest 117, 1627-1636 (2007). (Pubitemid 46871347)
17. Little, C.B. et al. Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development. Mol. Cell. Biol. 25, 3388-3399 (2005). (Pubitemid 40464337)
18. Little, C.B. et al. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum. 52, 1461-1472 (2005). (Pubitemid 40663938)
19. Farndale, R.W., Sayers, C.A. & Barrett, A.J. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect. Tissue Res. 9, 247-248 (1982). (Pubitemid 12009669)
20. Ratcliffe, A., Doherty, M., Maini, R.N. & Hardingham, T.E. Increased concentrations of proteoglycan components in the synovial fuids of patients with acute but not chronic joint disease. Ann. Rheum. Dis. 47, 826-832 (1988).
21. Farndale, R.W., Buttle, DJ. & Barrett, A.J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim. Biophys. Acta 883, 173-177 (1986). (Pubitemid 16027978)
22. Hollander, A.P., Atkins, R.M., Eastwood, D.M., Dieppe, P.A. & Elson, CJ. Human cartilage is degraded by rheumatoid arthritis synovial fuid but not by recombinant cytokines in vitro. Clin. Exp. Immunol. 83, 52-57 (1991).
23. Gregg, AJ. et al. Assessment of the catabolic effects of interleukin-1beta on proteoglycan metabolism in equine cartilage cocultured with synoviocytes. Am. J. Vet Res. 67, 957-962 (2006). (Pubitemid 43971110)
24. Tortorella, M.D. et al. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J. Biol. Chem. 275, 18566-18573 (2000). (Pubitemid 30414819)
25. Tortorella, M.D., Liu, R.Q., Burn, T., Newton, R.C. & Arner, E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specifcity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol. 21, 499-511 (2002). (Pubitemid 35248275)
26. Sandy, J.D., Thompson, V., Doege, K. & Verscharen, C The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1. Biochem. J. 351, 1-166 (2000).
27. Christner, J.E., Caterson, B. & Baker, J.R. Immunological determinants of proteoglycans. Antibodies against the unsaturated oligosaccharide products of chondroitinase ABC-digested cartilage proteoglycans. J. Biol. Chem. 255, 7102-7105 (1980). (Pubitemid 11232873)
28. Caterson, B., Calabro, A. & Hampton, A. In Biology of the Extracellular Matrix (eds. Wight, T. & Mecham, R.) 1-26 (Academic Press, 1987).
29. Sandy, J.D., Gamett, D., Thompson, V. & Verscharen, C Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem. J. 335, 59-66 (1998). (Pubitemid 28477050)
30. Struglics, A., Larsson, S., Hansson, M. & Lohmander, L.S. Western blot quantifcation of aggrecan fragments in human synovial fuid indicates differences in fragment patterns between joint diseases. Osteoarthr. Cartil. 17, 497-506 (2009).
31. Bitter, T. & Muir, H.M. A modifed uronic acid carbazole reaction. Anal. Biochem. 4, 330-334 (1962).
32. Björnsson, S. Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue. Anal. Biochem. 210, 282-291 (1993). (Pubitemid 23171019)
33. Swearingen, C et al. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fuid, serum and urine. Osteoarthr. Cartil. 18, 1150-1158 (2010).
34. Hughes, C.E., Caterson, B., Fosang, AJ., Roughley, PJ. & Mort, J.S. Monoclonal antibodies that specifcally recognise neo-epitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem. J. 305, 799-804 (1995).
35. Dufeld, D.R. et al. An immunoaffnity LC/MS/MS Assay for detection of endogenous aggrecan fragments in biological fuids. Use as a biomarker for aggrecanase activity and cartilage degradation. Anal. Biochem. 406, 113-123 (2010).
36. Drissi, H., Zuscik, M., Rosier, R. & O'Keefe, R. Transcriptional regulation of chondrocyte maturation: potential involvement of transcription factors in OA pathogenesis. Mol. Aspects Med. 26, 169-179 (2005). (Pubitemid 40462025)
37. Glasson, S.S. et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum. 50, 2547-2558 (2004). (Pubitemid 39062716)
38. Glasson, S.S. et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434, 644-648 (2005). (Pubitemid 40488556)
39. Echtermeyer, F. et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. Nat Med. 15, 1072-1077 (2009).
40. Miyaki, S. et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 24, 1173-1185 (2010).
41. Goldring, M.B., Otero, M., Tsuchimochi, K., Ijiri, K. & Li, Y. Defning the roles of infammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis. 67 (Suppl 3), iii75-iii82 (2008).
42. Luyten, F.P., Tylzanowski, P. & Lories, RJ. Wnt signaling and osteoarthritis. Bone 44, 522-527 (2009).
43. Chun, J.S., Oh, H., Yang, S. & Park, M. Wnt signaling in cartilage development and degeneration. BMB Rep. 41, 485-494 (2008).
44. Iliopoulos, D., Malizos, K.N., Oikonomou, P. & Tsezou, A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and infammatory networks. PLoS ONE 3, e3740 (2008).
45. Miyaki, S. et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum. 60, 2723-2730 (2009).
46. Sandell, LJ. et al. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthr. Cartil. 16, 1560-1571 (2008).
47. Appleton, C.T., Pitelka, V., Henry, J. & Beier, F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum. 56, 1854-1868 (2007). (Pubitemid 47110385)
48. Dell'accio, F., De Bari, C., Eltawil, N.M., Vanhummelen, P. & Pitzalis, C Identifcation of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. Arthritis Rheum. 58, 1410-1421 (2008). (Pubitemid 351705930)
49. Amaral, P.P., Dinger, M.E., Mercer, T.R. & Mattick, J.S. The eukaryotic genome as an RNA machine. Science 319, 1787-1789 (2008). (Pubitemid 351451554)
50. Fosang, AJ., Last, K., Gardiner, P., Jackson, D.C. & Brown, L. Development of a cleavage site-specifc monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fuids. Biochem. J. 310, 337-343 (1995).
51. Mercuri, F.A. et al. Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specifcity for matrix metalloproteinases and aggrecanase. J. Biol. Chem. 274, 32387-32395 (1999).
52. Fosang, AJ. et al. Neoepitope antibodies against MMP-cleaved and aggrecanase-cleaved aggrecan. Methods Mol. Biol. 622, 312-347 (2010).
53. Lark, M.W. et al. Quantifcation of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecifc anti-peptide serum. Biochem. J. 307, 245-252 (1995).
54. Lark, M.W. et al. Aggrecan degradation in human cartilage. Evidence for both metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J. Clin. Invest 100, 93-106 (1997). (Pubitemid 27311247)
55. Bayne, E.K. et al. Use of an antibody against the matrix metalloproteinase-generated aggrecan neoepitope FVDIPEN-COOH to assess the effects of stromelysin in a rabbit model of cartilage degradation. Arthritis Rheum. 38, 1400-1409 (1995).
56. van Meurs, J. et al. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum. 42, 2074-2084 (1999). (Pubitemid 30263590)
57. Chambers, M.G. et al. Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum. 44, 1455-1465 (2001). (Pubitemid 32537547)
58. Lee, E.R. et al. Immunolocalization of the cleavage of the aggrecan core protein at the Asn341-Phe342 bond, as an indicator of the location of the metalloproteinases active in the lysis of the rat growth plate. Anat Rec 252, 117-132 (1998). (Pubitemid 28397565)
59. Janusz, MJ. et al. Detection of aggrecanase-and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration. Osteoarthr. Cartil. 12, 720-728 (2004). (Pubitemid 39172748)
60. Maehara, H. et al. G1-G2 aggrecan product that can be generated by M-calpain on truncation at Ala709-Ala710 is present abundantly in human articular cartilage. J. Biochem. 141, 469-477 (2007). (Pubitemid 351455299)
61. Oshita, H. et al. Mature bovine articular cartilage contains abundant aggrecan that is C-terminally truncated at Ala719-Ala720, a site which is readily cleaved by m-calpain. Biochem. J. 382, 253-259 (2004). (Pubitemid 39141589)
62. Struglics, A. & Hansson, M. Calpain is involved in C-terminal truncation of human aggrecan. Biochem. J. 430, 531-538 (2010).
63. Chamberland, A. et al. Identifcation of a novel HtrA1-susceptible cleavage site in human aggrecan: evidence for the involvement of HtrA1 in aggrecan proteolysis in vivo. J. Biol. Chem. 284, 27352-27359 (2009).
64. Kadri, A. et al. Inhibition of bone resorption blunts osteoarthritis in mice with high bone remodelling. Ann. Rheum. Dis. 69, 1533-1538 (2010).
65. Rogerson, F.M., Chung, Y.M., Deutscher, M.E., Last, K. & Fosang, AJ. Cytokine-induced increases in ADAMTS-4 mRNA expression do not lead to increased aggrecanase activity in ADAMTS-5-defcient mice. Arthritis Rheum. 62, 3365-3373 (2010).
66. Ranstam, J. Reporting laboratory experiments. Osteoarthr. Cartil. 18, 3-4 (2010).
67. Arner, E.C., Hughes, C.E., Decicco, C.P., Caterson, B. & Tortorella, M.D. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthr. Cartil. 6, 214-228 (1998). (Pubitemid 28255112)
68. Gendron, C., Kashiwagi, M., Hughes, C., Caterson, B. & Nagase, H. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett 555, 431-436 (2003). (Pubitemid 37532588)
69. Little, C.B. et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem. J. 344, 62-68 (1999).
70. Frank, J.E., Thompson, V.P., Brown, M.P. & Sandy, J.D. Removal of O-linked and N-linked oligosaccharides is required for optimum detection of NITEGE neoepitope on ADAMTS4-digested fetal aggrecans: implications for specifc N-linked glycan-dependent aggrecanolysis at Glu373-Ala374. Osteoarthr. Cartil. 17, 777-781 (2009).
71. Barry, F.P., Rosenberg, L.C., Gaw, J.U., Koob, TJ. & Neame, PJ. N-and O-linked keratan sulfate on the hyaluronan binding region of aggrecan from mature and immature bovine cartilage. J. Biol. Chem. 270, 20516-20524 (1995).
72. Struglics, A. et al. Human osteoarthritis synovial fuid and joint cartilage contain both aggrecanase-and matrix metalloproteinase-generated aggrecan fragments. Osteoarthr. Cartil. 14, 101-113 (2006). (Pubitemid 43079306)
73. Lark, M.W. et al Cell-mediated catabolism of aggrecan. Evidence that cleavage at the 'aggrecanase' site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J. Biol. Chem. 270, 2550-2556 (1995).
74. Sztrolovics, R., Alini, M., Roughley, PJ. & Mort, J.S. Aggrecan degradation in human intervertebral disc and articular cartilage. Biochem. J. 326, 235-241 (1997). (Pubitemid 27386941)
75. Bayliss, M.T., Hutton, S., Hayward, J. & Maciewicz, R.A. Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: the infuence of age, topography and zone of tissue. Osteoarthr. Cartil. 9, 553-560 (2001). (Pubitemid 32842634)
76. Struglics, A., Larsson, S. & Lohmander, L.S. Estimation of the identity of proteolytic aggrecan fragments using PAGE migration and Western immunoblot. Osteoarthr. Cartil. 14, 898-905 (2006). (Pubitemid 44138667)